Attovia Therapeutics, a clinical-stage biopharmaceutical company, priced its upsized initial public offering at $17 per share, selling 17 million shares to raise approximately $289 million before expenses. The company focuses on developing next-generation biotherapeutics for immune-mediated diseases with high unmet needs. Attovia's stock is set to begin trading on Nasdaq under the symbol 'ATTO' on August 5, 2026. The funds will support ongoing development of its lead drug candidates targeting chronic pruritic diseases, atopic dermatitis, and inflammatory bowel disease.
As of June 30, 2026, thirty institutional investors collectively held about $74.9 million in Hyperliquid ETF products, with Brazil's Wealth High Governance Asset Management leading at nearly $24 million in the 21Shares' THYP fund. These ETFs track th...
Useless Coin (USELESS) hit a 10-month high of $0.286 after rallying 300% in a week, driven by strong buying and new holders. Despite intense buying pressure and positive momentum indicators, the rally may be overextended, suggesting a potential pullb...
The Seattle Times and Newsday have filed lawsuits against OpenAI and Microsoft, accusing them of using their journalism content without permission to train AI models. The lawsuits warn that generative AI could severely damage the journalism industry ...
Tokenized stocks on Solana and Robinhood Chain have reached $152 million in combined DeFi deposits, representing about 79% of the global tokenized-equity DeFi total value locked (TVL). Solana leads with $75.4 million, accounting for 64.5% of the mark...
Bitwise CIO Matt Hougan highlights three main crypto investment themes: Bitcoin as a hedge against currency debasement, Zcash for privacy, and a decade-long tokenization trend involving assets like ETH, SOL, and UNI. He predicts Bitcoin will break it...
